Kura Oncology Inc (NASDAQ:KURA) Shares Acquired by Eagle Asset Management Inc.

Eagle Asset Management Inc. boosted its holdings in shares of Kura Oncology Inc (NASDAQ:KURA) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,075,747 shares of the company’s stock after purchasing an additional 31,878 shares during the period. Eagle Asset Management Inc. owned approximately 4.59% of Kura Oncology worth $31,489,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. CVI Holdings LLC acquired a new stake in Kura Oncology during the second quarter valued at approximately $1,197,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after purchasing an additional 2,420 shares during the last quarter. Swiss National Bank lifted its stake in Kura Oncology by 36.1% during the second quarter. Swiss National Bank now owns 61,400 shares of the company’s stock valued at $1,209,000 after purchasing an additional 16,300 shares during the last quarter. Fosun International Ltd lifted its stake in Kura Oncology by 21.2% during the second quarter. Fosun International Ltd now owns 370,958 shares of the company’s stock valued at $7,341,000 after purchasing an additional 65,000 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its stake in Kura Oncology by 38.7% during the second quarter. Allianz Asset Management GmbH now owns 127,534 shares of the company’s stock valued at $2,511,000 after purchasing an additional 35,600 shares during the last quarter. 84.97% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently commented on KURA shares. Deutsche Bank started coverage on shares of Kura Oncology in a research report on Thursday, July 18th. They issued a “buy” rating and a $28.00 price target for the company. ValuEngine downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. JMP Securities restated a “market outperform” rating and issued a $22.00 price target on shares of Kura Oncology in a research report on Thursday, September 5th. BidaskClub upgraded shares of Kura Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, October 18th. Finally, Wedbush restated a “positive” rating on shares of Kura Oncology in a research report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.11.

Shares of NASDAQ:KURA traded up $0.39 during mid-day trading on Friday, hitting $15.53. The stock had a trading volume of 128,700 shares, compared to its average volume of 264,753. The company’s 50 day moving average is $14.92 and its 200-day moving average is $16.88. The company has a market cap of $672.35 million, a PE ratio of -9.03 and a beta of 2.57. Kura Oncology Inc has a 12-month low of $11.01 and a 12-month high of $21.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 23.50 and a current ratio of 23.50.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts predict that Kura Oncology Inc will post -1.61 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Article: How does a reverse stock split work?

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.